Natera, Inc. (NASDAQ:NTRA) Position Raised by EFG Asset Management Americas Corp.

EFG Asset Management Americas Corp. raised its stake in Natera, Inc. (NASDAQ:NTRA) by 277.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,311 shares of the medical research company’s stock after buying an additional 9,784 shares during the period. EFG Asset Management Americas Corp.’s holdings in Natera were worth $1,441,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of Natera by 0.7% in the first quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company’s stock valued at $1,010,152,000 after buying an additional 72,848 shares in the last quarter. Farallon Capital Management LLC increased its holdings in shares of Natera by 13.0% in the first quarter. Farallon Capital Management LLC now owns 3,927,683 shares of the medical research company’s stock valued at $359,226,000 after buying an additional 452,800 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of Natera by 7.1% in the fourth quarter. Principal Financial Group Inc. now owns 1,703,615 shares of the medical research company’s stock valued at $106,714,000 after buying an additional 112,825 shares in the last quarter. Norges Bank bought a new position in shares of Natera in the fourth quarter valued at $83,970,000. Finally, Avidity Partners Management LP increased its holdings in shares of Natera by 23.5% in the fourth quarter. Avidity Partners Management LP now owns 1,110,000 shares of the medical research company’s stock valued at $69,530,000 after buying an additional 211,000 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Insiders Place Their Bets

In other Natera news, insider Jonathan Sheena sold 12,000 shares of the business’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $121.01, for a total transaction of $1,452,120.00. Following the completion of the transaction, the insider now owns 287,441 shares of the company’s stock, valued at approximately $34,783,235.41. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, insider Solomon Moshkevich sold 549 shares of the company’s stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $105.16, for a total transaction of $57,732.84. Following the completion of the transaction, the insider now owns 113,637 shares of the company’s stock, valued at $11,950,066.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jonathan Sheena sold 12,000 shares of the stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $121.01, for a total transaction of $1,452,120.00. Following the completion of the transaction, the insider now directly owns 287,441 shares of the company’s stock, valued at approximately $34,783,235.41. The disclosure for this sale can be found here. Insiders sold a total of 92,388 shares of company stock valued at $10,205,064 in the last quarter. Insiders own 7.60% of the company’s stock.

Natera Stock Down 3.9 %

NASDAQ:NTRA traded down $4.60 during trading hours on Friday, reaching $112.90. The company’s stock had a trading volume of 946,364 shares, compared to its average volume of 1,379,358. The company has a market cap of $13.86 billion, a price-to-earnings ratio of -36.19 and a beta of 1.48. Natera, Inc. has a one year low of $36.90 and a one year high of $124.83. The business’s 50-day moving average is $111.58 and its 200-day moving average is $102.00. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. The firm had revenue of $413.35 million during the quarter, compared to analyst estimates of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The business’s revenue was up 58.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.97) EPS. Equities research analysts predict that Natera, Inc. will post -2.03 EPS for the current year.

Analysts Set New Price Targets

NTRA has been the topic of several recent analyst reports. BTIG Research boosted their target price on shares of Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Friday, August 9th. TD Cowen boosted their target price on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Piper Sandler boosted their target price on shares of Natera from $120.00 to $150.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. Stephens reissued an “overweight” rating and set a $125.00 target price on shares of Natera in a research note on Friday, August 9th. Finally, Morgan Stanley boosted their target price on shares of Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and a consensus target price of $120.07.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.